AI-driven antibody therapeutics for neurological diseases
AimedBio (AI MedBio) is a South Korean biotechnology company founded in 2018 as a spin-off from Samsung Medical Center. The company applies multi-omics and AI-driven big data analysis to discover and develop antibody-based therapeutics, with a focus on antibody-drug conjugates (ADCs) and bispecific antibodies targeting severe neurological diseases including brain cancer, Alzheimer's disease, and Parkinson's disease. AimedBio has entered strategic research collaborations with Samsung Biologics and AIVIS for AI-based biomarker quantification, and signed a $1B+ licensing deal with Boehringer Ingelheim for a novel ADC asset targeting solid tumors in 2025.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
